Rational antibody design for undruggable targets using kinetically controlled biomolecular probes.

Autor: Trkulja CL; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden., Jungholm O; Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden., Davidson M; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden., Jardemark K; Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden., Marcus MM; Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden., Hägglund J; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden.; Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden., Karlsson A; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden.; Nanoxis Consulting AB, SE-40016 Gothenburg, Sweden., Karlsson R; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden.; Nanoxis Consulting AB, SE-40016 Gothenburg, Sweden., Bruton J; Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden., Ivarsson N; Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden., Srinivasa SP; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden., Cavallin A; Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden., Svensson P; Integrative Research Laboratories, SE-41346, Gothenburg, Sweden., Jeffries GDM; Fluicell AB, SE-431 37 Mölndal, Sweden., Christakopoulou MN; Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden., Reymer A; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden.; Department of Chemistry and Molecular Biology, University of Gothenburg, SE-405 30 Gothenburg, Sweden., Ashok A; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden., Willman G; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden., Papadia D; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden., Johnsson E; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden., Orwar O; Oblique Therapeutics AB, SE-41346 Gothenburg, Sweden. owe.orwar@ki.se.; Department of Physiology and Pharmacology, Karolinska Institutet, SE-171 77 Stockholm, Sweden.

Publikováno v: Science advances [Sci Adv] 2021 Apr 16; Vol. 7 (16). Date of Electronic Publication: 2021 Apr 16 (Print Publication: 2021).

Effect of cholesterol depletion on the pore dilation of TRPV1.

Autor: Jansson ET; Department of Chemical and Biological Engineering, Chalmers University of Technology, SE-412 96 Göteborg, Sweden., Trkulja CL, Ahemaiti A, Millingen M, Jeffries GD, Jardemark K, Orwar O

Publikováno v: Molecular pain [Mol Pain] 2013 Jan 02; Vol. 9, pp. 1. Date of Electronic Publication: 2013 Jan 02.